The Food and Drug Administration announced Thursday it is requiring manufacturers of insomnia products, such as Ambien, Edluar and Zolpimist, to lower their current recommended doses.

The drugs contain an active ingredient called zolpidem, which causes drowsiness. Researchers have found high levels of zolpidem in the blood of some patients the morning after a dose — so much so it affects patients’ cognitive skills, including their ability to drive.

Also On The Light 103.9 FM: